Clinical News
2020-09-22
Olaparib and Durvalumab Combination Showed Promising Results in HER2-negative Breast Cancer Patients with Germline BRCA Mutation
MEDIOLA is a phase I/II basket trial of olaparib and durvalumab. In a study cohort of the MEDIOLA study, the combination of olaparib and durvalumab showed promising anti-tumor activity in HER2-negative gBRCA-mutated breast cancer.
Source:
Lancet Oncol.
2020-09-22
Ensartinib: A new TKI inhibitor prolonged PFS in ALK+ NSCLC patients
In a phase 3 study (eXalt3), ensartinib showed longer mPFS and higher intracranial ORR compared with crizotinib. The results indicated ensartinib can be a new first-line treatment option for patients with ALK+ NSCLC.
Source:
IASLC WCLC 2020
2020-08-21
A new IDH1/2 inhibitor for mutated IDH1/2 low-grade glioma
In a phase I study, the anti-tumor activity of vorasidenib (VOR; AG-881) was demonstrated in mutated IDH1/2 low-grade glioma.
Source:
J Clin Oncol
2020-08-21
A new FGFR inhibitor for intrahepatic cholangiocarcinoma treatment
In a phase 2 study, futibatinib showed anti-tumor efficacy in chemotherapy-treated intrahepatic cholangiocarcinoma with FGFR2 fusion
Source:
J Clin Oncol
2020-08-21
ESR1 Mutation as a Prediction Marker for 1st-line AI plus CDK4/6 Inhibitor in HR+ Breast Cancer Patients
In phase 3 PADA-1 study, HR+ breast cancer patients with an ESR1 mutation showed worse outcomes in response to the 1st-line combination therapy of AI and palbociclib. Moreover, the reduction of plasma ESR1 mutation ctDNA level in the early stage of treatm
Source:
J Clin Oncol
2020-07-22
Capmatinib showed anti-tumor activity in MET-amplified advanced NSCLC
MET amplification is one of the driver genetic alterations in advanced NSCLC. In a phase II study, the anti-tumor activity of capmatinib was demonstrated in treatment-na?ve and pretreated patients with MET-amplified advanced NSCLC.
Source:
J Clin Oncol
2020-07-22
LRP1B pathogenic mutations were associated with clinical benefits on immunotherapy treatment
The immunotherapy-related biomarkers other than PD-L1, MSI-H/dMMR or TMB are still under development. A study analyzed the immunotherapy clinical outcome in cancer patients with LRP1B mutations. The results indicated the LRP1B pathogenic mutations were as
Source:
J Clin Oncol
2020-07-22
Olaparib demonstrates anti-tumor activities in metastatic breast cancer patients harbored a mutation in homologous recombination repair pathway genes
Recently, phase 2 TBCRC 048 study results were published at the 2020 ASCO Virtual Scientific Program. This study aimed to investigate the activities of olaparib in metastatic breast cancer patients who have a homologous recombination repair gene mutation.
Source:
J Clin Oncol
2020-07-08
Is Immunotherapy Right for Me?
Cancer immunotherapy has been hailed as the most promising treatment against cancer in recent decades, but what exactly is immunotherapy? Is Immunotherapy right for me?
Source:
2020-07-07
Merck’s Keytruda grasps FDA approval again with TMB-H biomarker regardless of tumor type
Merck is proficient in the mechanism of immunotherapy, and after Keytruda's first approval in 2017 with MSI-H as biomarker regardless of where in the body cancer started, the same approval came in June 2020 with TMB-H, showing prospects in immunotherapy.
Source:
Fierce Pharma
